Boston Scientific approves $700M-$800M restructuring plan through 2029

Boston Scientific Corp. (NYSE: BSX) said its board of directors approved a global restructuring program on July 21, 2026, estimated to cost between $700 million and $800 million in total pre-tax charges.

The 2026 Restructuring Plan includes supply chain optimization, production line transfers between facilities, and organizational changes. Activities are expected to begin in 2026 and be substantially completed by the end of 2029.

Of the total estimated charges, approximately $600 million to $700 million is expected to result in future cash outlays. The plan is projected to reduce gross annual pre-tax expenses by approximately $500 million once fully realized, with a substantial portion of those savings intended for reinvestment in growth initiatives.

The estimated charges break down as follows: $300 million to $350 million in production transfer costs, $275 million to $300 million in employee termination benefits, and $125 million to $150 million in other costs including consulting fees, contract cancellations, program management, and asset write-offs.

The company said the restructuring activities are expected to result in some headcount reductions, while new positions will be created in areas of growth. Specific employee impact plans will be developed for each affected region and business unit, in coordination with employee representative bodies where required by local law.

You May Also Be Interested In

• Ryanair signs five-year cloud and AI deal with Google
• CoreWeave (CRWV) PT Raised to $87 at TD Cowen
• BofA Securities: 'INTC well positioned to address $380B CY30 foundry TAM'